News
-
-
COMMUNIQUÉ DE PRESSE
PharmaSGP with significant increase in revenues and EBITDA in 2024
PharmaSGP Holding SE achieved significant revenue and EBITDA growth in 2024. Revenues increased by 17.5% to €118.8 million, with adjusted EBITDA reaching €37.2 million. Management foresees further growth in 2025 amidst global uncertainty -
-
-
COMMUNIQUÉ DE PRESSE
PharmaSGP with strong revenues growth in 9M 2024 – revenues forecast for FY 2024 raised
PharmaSGP Holding SE reports strong revenue growth in 9 months of 2024, with preliminary figures showing a 17.0% increase compared to the same period last year. FY 2024 revenue forecast raised -
-
-
-
-